Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer
The advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors (TKIs) has considerably transformed the therapeutic management of a subset of patients with non-small cell lung cancer (NSCLC) harboring defined molecular abnormalities. When such genetic molecular alterati...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00281/full |
| _version_ | 1811303697274109952 |
|---|---|
| author | Vincent eFaugeroux Vincent eFaugeroux Emma ePailler Emma ePailler Nathalie eAuger Meilissa eTaylor Meilissa eTaylor Françoise eFarace Françoise eFarace |
| author_facet | Vincent eFaugeroux Vincent eFaugeroux Emma ePailler Emma ePailler Nathalie eAuger Meilissa eTaylor Meilissa eTaylor Françoise eFarace Françoise eFarace |
| author_sort | Vincent eFaugeroux |
| collection | DOAJ |
| description | The advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors (TKIs) has considerably transformed the therapeutic management of a subset of patients with non-small cell lung cancer (NSCLC) harboring defined molecular abnormalities. When such genetic molecular alterations are detected the use of specific TKI has demonstrated better results (overall response rate (ORR), progression free survival (PFS)) compared to systemic therapy. However the detection of such molecular abnormalities is complicated by the difficulty in obtaining sufficient tumor material, in terms of quantity and quality, from a biopsy. Here we described how circulating tumor cells (CTCs) can have a clinical utility in ALK (anaplastic lymphoma kinase) positive NSCLC patients to diagnose ALK-EML4 gene rearrangement and to guide therapeutic management of these patients. The ability to detect genetic abnormalities such ALK rearrangement in CTCs shows that these cells could offer new perspectives both for the diagnosis and the monitoring of ALK-positive patients eligible for treatment with ALK inhibitors. |
| first_indexed | 2024-04-13T07:52:40Z |
| format | Article |
| id | doaj.art-8423d7572c4d4928a2505f2629dcbc16 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T07:52:40Z |
| publishDate | 2014-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8423d7572c4d4928a2505f2629dcbc162022-12-22T02:55:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-11-01410.3389/fonc.2014.00281112513Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung CancerVincent eFaugeroux0Vincent eFaugeroux1Emma ePailler2Emma ePailler3Nathalie eAuger4Meilissa eTaylor5Meilissa eTaylor6Françoise eFarace7Françoise eFarace8Gustave RoussyGustave RoussyGustave RoussyGustave RoussyGustave RoussyGustave RoussyGustave RoussyGustave RoussyGustave RoussyThe advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors (TKIs) has considerably transformed the therapeutic management of a subset of patients with non-small cell lung cancer (NSCLC) harboring defined molecular abnormalities. When such genetic molecular alterations are detected the use of specific TKI has demonstrated better results (overall response rate (ORR), progression free survival (PFS)) compared to systemic therapy. However the detection of such molecular abnormalities is complicated by the difficulty in obtaining sufficient tumor material, in terms of quantity and quality, from a biopsy. Here we described how circulating tumor cells (CTCs) can have a clinical utility in ALK (anaplastic lymphoma kinase) positive NSCLC patients to diagnose ALK-EML4 gene rearrangement and to guide therapeutic management of these patients. The ability to detect genetic abnormalities such ALK rearrangement in CTCs shows that these cells could offer new perspectives both for the diagnosis and the monitoring of ALK-positive patients eligible for treatment with ALK inhibitors.http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00281/fulltargeted therapyCirculating Tumor Cells (CTCs)predictive biomarkerALK rearrangementnon-small-cell lung cancer (NSCLC) |
| spellingShingle | Vincent eFaugeroux Vincent eFaugeroux Emma ePailler Emma ePailler Nathalie eAuger Meilissa eTaylor Meilissa eTaylor Françoise eFarace Françoise eFarace Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer Frontiers in Oncology targeted therapy Circulating Tumor Cells (CTCs) predictive biomarker ALK rearrangement non-small-cell lung cancer (NSCLC) |
| title | Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer |
| title_full | Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer |
| title_fullStr | Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer |
| title_full_unstemmed | Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer |
| title_short | Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer |
| title_sort | clinical utility of circulating tumor cells in alk positive non small cell lung cancer |
| topic | targeted therapy Circulating Tumor Cells (CTCs) predictive biomarker ALK rearrangement non-small-cell lung cancer (NSCLC) |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00281/full |
| work_keys_str_mv | AT vincentefaugeroux clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT vincentefaugeroux clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT emmaepailler clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT emmaepailler clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT nathalieeauger clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT meilissaetaylor clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT meilissaetaylor clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT francoiseefarace clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer AT francoiseefarace clinicalutilityofcirculatingtumorcellsinalkpositivenonsmallcelllungcancer |